JIR
RGNX icon

James Investment Research’s Regenxbio RGNX Stock Holding History

James Investment Research’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,435
Closed -$713K – 767
2019
Q1 		$713K Sell
12,435
-9,665
-44% -$479K 0.05% 297
2018
Q4 		$927K Buy
+22,100
New +$1.3M 0.06% 410

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

James Investment Research's RGNX Position: Q2 2019 in Review

James Investment Research sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 12,435 shares — an estimated $713K sold.

James Investment Research first reported a position in RGNX in Q4 2018 and held it in 2 quarters. The position peaked at $927K in Q4 2018. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

  • James Investment Research reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
  • James Investment Research sold 12,435 Regenxbio shares in Q2 2019, an estimated $713K.
  • James Investment Research first reported a position in Regenxbio in Q4 2018 and held it in 2 quarters.
  • James Investment Research's Regenxbio position peaked at $927K in Q4 2018.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on James Investment Research's 13F filing for Q2 2019, filed 24 Jul 2019.